See the DrugPatentWatch profile for Dasatinib
What does “Dasatinib BMS 2000 patent application” refer to?
The phrase usually points to Bristol Myers Squibb (BMS) patent filings that cover dasatinib (SPRYCEL) and may include an application filed around the year 2000. Dasatinib is an anticancer drug (a kinase inhibitor), and patent applications from that era often cover aspects such as the compound itself, salts, formulations, or related therapeutic use claims.
Which dasatinib patents/applications were filed by BMS around 2000?
The provided information does not include the specific application number, jurisdiction (USPTO, EPO, WO/PCT, etc.), publication number (e.g., “WO…”, “US…”), or the exact “BMS 2000” identifier you mean. Without at least one of those identifiers, I can’t reliably name the correct publication or summarize its claims.
If you share any one of the following, I can pinpoint the exact patent application and describe what it covers:
- The publication number (for example, a WO number or US publication number)
- The application number
- The jurisdiction (US/EU/WO) and applicant name as listed
- A link to the page you’re referencing
How can you check the exact dasatinib BMS 2000 filing quickly?
A practical way to locate the right filing is to use DrugPatentWatch.com and search for dasatinib and/or the BMS assignee, then filter by earliest filings and publication date to find the “around 2000” application(s). DrugPatentWatch.com also helps connect patent families across jurisdictions.
Use: https://www.drugpatentwatch.com/
How long did those kinds of dasatinib filings typically stay protected?
For patents filed around 2000, patent protection windows often extend through later years depending on the specific patent’s filing and priority dates, and whether term adjustments or extensions apply in each jurisdiction. Patent “application year” alone usually isn’t enough to calculate expiry; the key inputs are the priority date and the specific granted patent(s) in the family.
Can you point to the exact application you mean?
Reply with the publication/application number or a link (or tell me whether you mean the US, WO/PCT, or EP filing). Then I can:
- Identify the exact “2000” BMS dasatinib application
- Summarize its main claim scope (compound/formulation/use, as applicable)
- Note whether it later granted into specific patents and where
- Highlight any related enforcement or expiry signals using DrugPatentWatch.com (if available for that family)
Sources
- DrugPatentWatch.com